Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants코로나바이러스 질병 재조합 소단위 백신의 세 번째 용량으로 이종 부스팅은 다양한 중증 급성 호흡기 증후군 코로나바이러스 2 변이체에 대한 중화 항체 및 T 세포 면역을 증가시킵니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Anti-RBD IgG anti-S booster vaccination CD4+ T cell components composite pattern coronavirus coronavirus disease COVID-19 COVID-19 vaccinations COVID-19 vaccine dose effective epitope Epitopes evaluated Evidence help Heterologous heterologous boosting homologous Humoral immunity Immune escape Immunity immunization strategy immunological in some inactivated Inactivated vaccine increase magnitude NAb NAbs natural infection Neutralizing Neutralizing antibodies neutralizing antibody neutralizing capacity omicron pandemic prime-boost strategy produced RBD IgG respiratory subunit Subunit vaccine Subunit vaccine. T cell T cell response T cells titre vaccination Vaccination strategies Vaccination strategy Vaccine Vaccine-induced immunity variant variants of concern waned [DOI] 10.1080/22221751.2022.2048969 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective studyArticle Published on 2022-11-302022-11-15 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] acute respiratory syndrome antibodies antibody Blood C-reactive protein carried Cell China CLIA Coronavirus-2 COVID-19 COVID-19 vaccination COVID-19 vaccine decrease described detect distribution dose effective Effectiveness healthy control high-risk population ICV IgG immunization immunoassay immunogenicity immunosuppressive agent inactivated Inactivated vaccine Infection inoculated Logistic regression analysis magnitude methotrexate parameter Patient patients patients treated positive response Prednisolone Prospective Study Protective antibody receiving recruited response to vaccination rheumatic disease Safe Safety Safety. SARS-CoV-2 serious adverse reaction South [DOI] 10.1080/21645515.2022.2090176 PMC 바로가기
One-click investigation of shape influence of silver nanostructures on SERS performance for sensitive detection of COVID-19Article Published on 2022-11-222022-11-15 Journal: Analytica chimica acta [Category] COVID19(2023년), SARS, 치료기술, [키워드] Ag nanostructure approach Concentration COVID-19 dendritic Diagnosis Diseases indicated investigated magnitude Microdroplets array Mini-pillar platform morphology multiple parameter Novel coronavirus provide reproducibility RNA sequence SARS-CoV-2 sensitive sensitivity SERS. the SARS-CoV-2 transfer [DOI] 10.1016/j.aca.2022.340523 PMC 바로가기
Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide AptamerArticle Published on 2022-11-022022-11-15 Journal: ACS applied materials & interfaces [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] acute respiratory syndrome Analysis Antibody-derived peptide aptamer (ADPA) applied aptamer Biomarker coronavirus COVID-19 patients cytokine detection Detection limit Disease progression disorders enhanced IL-6 immune pathway Immune status immunoassay immunoassays in vitro induced Inflammation inflammatory status information interleukin 6 (IL-6 Interluekin-6 (IL-6) Interpretation limit of detection localized surface plasmon resonance (LSPR) magnitude nanoplasmonic immunoassay pandemic pathogenic inflammation Patient peptide Predictive profile Prognosis provide quantification Rapid SARS-CoV-2 serum serum cytokine Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). [DOI] 10.1021/acsami.2c14748 PMC 바로가기
Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severityReview article Published on 2022-11-012022-10-05 Journal: Gene [Category] SARS, 바이오마커, 변종, 유전자 메커니즘, [키워드] ACE1 ACE2 AGTR1 ApoE association Case-control CCR5 Clinical outcome contribute contributing to Control correlation country COVID-19 COVID-19 pandemic COVID-19 susceptibility Critical eligible Evidence exacerbated examined Factor Genes Genetic genetic determinant Genetic polymorphism Genetic variant greater Health Healthcare system Host host genetics human gene I/D identify IFITM3 implicated increased risk increasingly infected individual infected individuals Infection investigated magnitude manifestation Manifestations Meta-analysis meta-analysis mutations Patient performed polymorphism progression provide required Research rs2285666 SARS-CoV-2 severe COVID-19 severity Statistical power statistically significant susceptibility systematic review variant with COVID-19 [DOI] 10.1016/j.gene.2022.146790 [Article Type] Review article
Antibody response to COVID-19 vaccines among workers with a wide range of exposure to per- and polyfluoroalkyl substancesArticle Published on 2022-11-012022-11-15 Journal: Environment international [Category] 진단, [키워드] 95% CI adjusted affected analyses Analysis anti-Spike IgG antibody antigenic association coefficient comparable Concentration confidence interval Coronavirus disease 2019 COVID-19 COVID-19 antibody COVID-19 vaccination COVID-19 vaccine disease Enrollment examined follow-up study group Human IgG increase in interquartile range magnitude neutralizing antibody observation Occurrence other variables participant Perfluoroalkyl substances PFAS Polyfluoroalkyl substances recent reduced repeated measure reported response serum shown spring sulfonic acid Tetanus vaccination Vaccine vaccine-induced antibody vaccine. [DOI] 10.1016/j.envint.2022.107537 PMC 바로가기
Serum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regressionArticle Published on 2022-11-012022-11-15 Journal: Clinical and experimental medicine [Category] 바이오마커, [키워드] 95% CI Admission alteration Analysis Biomarker certainty of evidence Concentration conducted coronavirus disease COVID-19 COVID-19 patients COVID-19 severity disease severity effect size Egger estimates heterogeneity hospitalized COVID-19 patient hydroxybutyrate hydroxybutyrate dehydrogenase Inflammation Injury Liver damage magnitude marker Meta-analysis meta-regression moderate Mortality mortality. Myocardial myocardial injury non-specific non-survivor Patient performed renal renal function reported risk stratification searched Sepsis serum severity significantly significantly higher SMD standardized mean difference survival survivor systematic review tissue damage Web of Science [DOI] 10.1007/s10238-021-00777-x PMC 바로가기
Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosisArticle Published on 2022-11-012022-11-16 Journal: Journal of hepatology [Category] SARS, 변종, [키워드] 95% CI appear B.1.1.529 B.1.617.2 BNT BNT162b2 BNT162b2 mRNA booster booster dose chronic liver disease cirrhosis compensated Control control group COVD-19 COVID-19 COVID-19 in patient COVID-19 vaccines COVID-19-related death Critical dose doses General population greater hepatic decompensation hyporesponsiveness immune dysregulation liver magnitude moderate Moderate COVID-19 Moderna mRNA-1273 vaccine mRNA vaccine mRNA-1273 mRNA-1273. outcome overcome participant Patient Pfizer predominant receipt reduction in retrospective cohort study risk of infection Support symptomatic the vaccine Vaccine Vaccines variants veteran with COVID-19 [DOI] 10.1016/j.jhep.2022.07.036 PMC 바로가기
Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trialsArticle Published on 2022-11-012022-11-15 Journal: European Journal of Clinical Pharmacology [Category] SARS, 치료제, [키워드] 95% CI 95% confidence interval addition anti-inflammatory effect antiparasitic antiviral activity blinded clinical benefit continuous variable COVID-19 D-dimer D-dimer level death dichotomous variable Disease progression Effect effect size Efficacy and safety element eligibility enrolled Evidence Frequency ICU admission in vitro individual Inflammation Invasive mechanical ventilation lactate dehydrogenase LDH magnitude Meta-analysis Mild moderate Moderate COVID-19 nitazoxanide no difference Patient patients peer-reviewed performed Placebo placebo-controlled positive positive RT-PCR Primary outcome randomized clinical trial RCT RCTs receiving reducing reduction in reported risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infection. secondary outcome serum biomarker SMD standardized mean difference systematic review tested to define treat treated Viral load WBC were used White blood cell with COVID-19 [DOI] 10.1007/s00228-022-03380-5 PMC 바로가기
Single-cell transcriptomic atlas reveals distinct immunological responses between COVID-19 vaccine and natural SARS-CoV-2 infectionArticle Published on 2022-11-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 유전자 메커니즘, 진단, [키워드] Activation acute respiratory syndrome alteration analysis antibody production Apoptosis B cell caused collected CoronaVac coronavirus COVID-19 COVID-19 infected patient COVID-19 patients COVID-19 vaccine cytotoxicity downregulation Emergency use authorization expression expression of gene feature greater HLA class II IL21R immune Immune cell immune cell types immune response immunization immunized immunological Immunological response immunological responses inactivated Inactivated vaccine individual individuals Infection Inflammatory cytokine innate immune cell interferon response magnitude mechanism Migration mononuclear cells naïve B cell naïve B cells pandemic PBMC Peripheral blood phenotype plasma profile Proinflammatory cytokine proportion provide reveal SARS-CoV-2 SARS-COV-2 infection scRNA-seq Sequencing severe disease single-cell Single-cell RNA sequencing single-cell sequencing. Sinovac systemic immune response T cell thrombosis transcriptomic upregulation vaccine-induced immune response [DOI] 10.1002/jmv.28012 PMC 바로가기